DK2146961T3 - N-oxid- og/eller di-N-oxidderivater af dopaminreceptorstabilisatorer/modulatorer udvisende forbedrede cardiovaskulære bivirkningsprofiler - Google Patents

N-oxid- og/eller di-N-oxidderivater af dopaminreceptorstabilisatorer/modulatorer udvisende forbedrede cardiovaskulære bivirkningsprofiler

Info

Publication number
DK2146961T3
DK2146961T3 DK08741904T DK08741904T DK2146961T3 DK 2146961 T3 DK2146961 T3 DK 2146961T3 DK 08741904 T DK08741904 T DK 08741904T DK 08741904 T DK08741904 T DK 08741904T DK 2146961 T3 DK2146961 T3 DK 2146961T3
Authority
DK
Denmark
Prior art keywords
oxide
side effects
dopamine receptor
exhibiting improved
cardiovascular side
Prior art date
Application number
DK08741904T
Other languages
English (en)
Inventor
Haakan V Wikstroem
Original Assignee
Ivax Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Int Gmbh filed Critical Ivax Int Gmbh
Application granted granted Critical
Publication of DK2146961T3 publication Critical patent/DK2146961T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK08741904T 2007-04-12 2008-04-11 N-oxid- og/eller di-N-oxidderivater af dopaminreceptorstabilisatorer/modulatorer udvisende forbedrede cardiovaskulære bivirkningsprofiler DK2146961T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0700893 2007-04-12
PCT/SE2008/050414 WO2008127188A1 (en) 2007-04-12 2008-04-11 N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles

Publications (1)

Publication Number Publication Date
DK2146961T3 true DK2146961T3 (da) 2014-04-28

Family

ID=39864178

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08741904T DK2146961T3 (da) 2007-04-12 2008-04-11 N-oxid- og/eller di-N-oxidderivater af dopaminreceptorstabilisatorer/modulatorer udvisende forbedrede cardiovaskulære bivirkningsprofiler

Country Status (19)

Country Link
US (1) US9139525B2 (da)
EP (1) EP2146961B1 (da)
JP (1) JP5393654B2 (da)
CN (1) CN101711236B (da)
AU (1) AU2008239841B2 (da)
BR (1) BRPI0810161A2 (da)
CA (1) CA2683719C (da)
CY (1) CY1115337T1 (da)
DK (1) DK2146961T3 (da)
ES (1) ES2458592T3 (da)
HR (1) HRP20140380T1 (da)
IL (1) IL201401A (da)
MX (1) MX2009011020A (da)
NZ (1) NZ580856A (da)
PL (1) PL2146961T3 (da)
PT (1) PT2146961E (da)
RU (1) RU2470013C2 (da)
SI (1) SI2146961T1 (da)
WO (1) WO2008127188A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
CA2744308C (en) * 2008-11-24 2017-05-30 Nsab, Filial Af Neurosearch Sweden Ab, Sverige 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
US9018202B2 (en) * 2010-12-03 2015-04-28 Allergan, Inc. Methods for treating diseases of the retina
BR112014005389A8 (pt) 2011-09-07 2018-04-03 Ivax Int Gmbh Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
TWI579272B (zh) 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽
AU2013243461A1 (en) 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
HK1221646A1 (zh) 2013-06-21 2017-06-09 Teva Pharmaceuticals International Gmbh 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
MX2017008136A (es) 2014-12-22 2018-03-06 Teva Pharmaceuticals Int Gmbh Sal de l-tartrato de pridopidina.
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
JP7034488B2 (ja) 2016-02-24 2022-03-14 プリレニア・ニューロセラピューティクス・エルティーディー プリドピジンを使用する神経変性眼疾患の治療
EP4516356A3 (en) 2016-08-24 2025-05-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
CA3035099C (en) 2016-08-24 2023-01-17 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating dystonias
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
CA3050700C (en) 2017-01-20 2023-10-03 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile x syndrome
SI4154882T1 (sl) 2017-08-14 2026-01-30 Prilenia Neurotherapeutics Ltd. Zdravljenje amiotrofične lateralne skleroze s pridopidinom
CA3073568A1 (en) 2017-08-30 2019-03-07 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
JP2020533296A (ja) 2017-09-08 2020-11-19 プリレニア ニューロセラピューティクス リミテッド 薬物誘発性ジスキネジアを治療するためのプリドピジン
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CN113395964A (zh) 2019-02-04 2021-09-14 普瑞尼亚神经治疗有限公司 用于帕金森氏病和与帕金森症相关的其它疾病的低剂量普利多匹定
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1217296A (en) 1917-01-11 1917-02-27 Lewis A Peckham Shock-absorber.
US2813098A (en) 1955-08-16 1957-11-12 Upjohn Co 3-methoxy-n-methylmorphinan n-oxide
US2813097A (en) 1955-08-16 1957-11-12 Upjohn Co 3-hydroxy-n-methylmorphinan-n-oxide
US3131185A (en) 1959-03-18 1964-04-28 Orsymonde Nicotinic esters of hydroxyl derivatives of the phenanthrenic alkaloids of opium, and process for the preparation of these esters
BE638369A (da) 1962-10-10
CH481123A (de) 1966-09-21 1969-11-15 Geigy Ag J R Verfahren zur Herstellung von neuen, kondensierten heterocyclischen Verbindungen
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
WO1992018475A2 (en) 1991-04-17 1992-10-29 The Upjohn Company Substituted phenylazacycloalkanes as cns agents
AU676993B2 (en) 1991-06-27 1997-04-10 Virginia Commonwealth University Sigma receptor ligands and the use thereof
IL112099A (en) * 1993-12-23 1999-07-14 Ortho Pharma Corp N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
JP2002530340A (ja) * 1998-11-23 2002-09-17 セプラコール， インク． オランザピン−ｎ−オキサイドを含む医薬組成物
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE0200301D0 (sv) * 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
MXPA06013941A (es) * 2004-06-08 2007-12-10 Neurosearch Sweden Ab Fenilpiperidinas disustituidas, novedosas, como moduladores de la neurotransmision de dopamina y serotonina.
ES2346452T3 (es) 2004-06-08 2010-10-15 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Nuevas fenilpiperidinas/piperazinas disustituidas utilizadas como moduladores de la neurotransmision de la dopamina.
MX2007001713A (es) * 2004-08-11 2007-07-13 Donald L Barbeau Compuestos farmaceuticos no cardiotoxicos.
CA2584831C (en) * 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
ATE417834T1 (de) * 2005-08-22 2009-01-15 Solvay Pharm Bv N-oxide als prodrugs von piperazin- und piperidinderivaten
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
WO2007128694A1 (en) * 2006-05-02 2007-11-15 Solvay Pharmaceuticals B.V. N-oxides of pyridylmethylpiperazine and -piperidine derivatives
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
WO2011107593A1 (en) * 2010-03-05 2011-09-09 Dsm Ip Assets B.V. Process for the production of an uhmwpe article
JP2013536825A (ja) * 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
BR112014005389A8 (pt) 2011-09-07 2018-04-03 Ivax Int Gmbh Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
TWI579272B (zh) * 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽
AU2013243461A1 (en) * 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
MX2015003608A (es) * 2012-09-27 2015-06-05 Teva Pharma Combinacion de laquinimod y pridopidina para tratar trastornos neurodegenerativos.
US20150216850A1 (en) * 2012-09-27 2015-08-06 Michael Hayden Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease

Also Published As

Publication number Publication date
CA2683719C (en) 2015-07-14
EP2146961B1 (en) 2014-01-29
CN101711236A (zh) 2010-05-19
ES2458592T3 (es) 2014-05-06
HRP20140380T1 (hr) 2014-08-15
AU2008239841B2 (en) 2013-07-18
CA2683719A1 (en) 2008-10-23
CY1115337T1 (el) 2017-01-04
SI2146961T1 (sl) 2014-08-29
CN101711236B (zh) 2012-10-31
EP2146961A1 (en) 2010-01-27
EP2146961A4 (en) 2011-08-03
IL201401A0 (en) 2010-05-31
PL2146961T3 (pl) 2014-09-30
JP5393654B2 (ja) 2014-01-22
PT2146961E (pt) 2014-04-30
IL201401A (en) 2015-10-29
RU2470013C2 (ru) 2012-12-20
JP2010523651A (ja) 2010-07-15
NZ580856A (en) 2011-11-25
WO2008127188A1 (en) 2008-10-23
US20100105736A1 (en) 2010-04-29
AU2008239841A1 (en) 2008-10-23
BRPI0810161A2 (pt) 2014-12-30
RU2009141300A (ru) 2011-05-20
MX2009011020A (es) 2009-10-30
US9139525B2 (en) 2015-09-22

Similar Documents

Publication Publication Date Title
DK2146961T3 (da) N-oxid- og/eller di-N-oxidderivater af dopaminreceptorstabilisatorer/modulatorer udvisende forbedrede cardiovaskulære bivirkningsprofiler
BRPI0906980A2 (pt) Composição de derivados e maleatados
PT3037529T (pt) Polipéptidos ph20 estendidos solúveis e suas utilizações
BRPI0908906A2 (pt) compostos heterocíclicos e usos dos mesmos
CY2017001PI2 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
BRPI0920354A2 (pt) derivados de indol e benzomorfolina como moduladores de receptores de glutamato metabotrópicos
BRPI0809930A2 (pt) Derivados de carboxamida imidazolidina como moduladores de p2x7
HRP20151052T1 (xx) Peteroäślani heterocikliäśki amidi i srodne tvari
ITMI20091978A1 (it) Componente micromeccanico
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
DE602008003532D1 (de) Winkelverstellbares Scharnier
BRPI0923497A2 (pt) derivados de piridazinona
DK2222669T3 (da) Oxadiazolderivater med virkning på sphingosin-1-phosphat (sip)
HRP20161562T1 (hr) Derivati benzimidazola
BRPI0921938A2 (pt) acionamento de ações de animação e ações de objeto de mídia
BRPI0921822A2 (pt) composição compreendendo polímero e enzima
DK2138716T3 (da) Vingeindsats
EP2356462A4 (en) ANTI-CXCR1 COMPOSITIONS AND METHOD
BRPI0908228A2 (pt) Dobradiça com dispositivo de amortecimento
BRPI0920183A2 (pt) derivados de fenetilamida e seus analogos heterociclicos
EP2392613A4 (en) CELLULOSE ARTIFICIAL RESIN COMPOSITION AND CELLULOSE ARTIFICIAL RESIN FILM
BRPI0822058A2 (pt) Derivados de 5-oxo-3-pirrolidinacarboxamida como moduladores de p2x7
DK2275414T3 (da) Cyclopentylacrylamidderivat
BRPI0924059A2 (pt) Didro piridona amidas como moduladores de p2x7
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate